RxDoctor Payments Data

Angela Ballard, APRN

Family · Richmond, KYNPI 1154673986

Payments from drug & device makers

$8,096in general payments, 2019–2025

Across 472 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Lilly USA, LLC$1K
  • Novartis$843
  • E.r. Squibb & Sons, L.L.C.$544
  • UCB, Inc.$358
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$7,67995%
  • Education$4175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,096 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$112,931
Medicare patients
669
Services billed
2,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab57$712,512
Skyrizi PenRisankizumab-Rzaa34$678,646
Cosentyx Sensoready (2 Pens)Secukinumab59$470,105
OtezlaApremilast93$434,611
Dupixent PenDupilumab73$272,785
Cosentyx Unoready PenSecukinumab29$234,773
StelaraUstekinumab11$202,779
EnbrelEtanercept13$139,524
Enbrel SureclickEtanercept14$102,933
Taltz AutoinjectorIxekizumab13$87,955
Humira(Cf)Adalimumab11$74,838
Dupixent SyringeDupilumab20$74,758
XolairOmalizumab23$65,565
Clobetasol Propionate90$4,896
Triamcinolone Acetonide301$4,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$148$574,135106 claims
Johnson & JohnsonStelara$1,241$202,77911 claims
AbbVieHumira(Cf)$1,581$74,83811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Richmond

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →